Myeloma bone disease

被引:25
作者
Berenson, JR [1 ]
机构
[1] Inst Myeloma & Bone Canc Res, W Hollywood, CA 90069 USA
关键词
myeloma bone disease; bisphosphonates;
D O I
10.1016/j.beha.2005.03.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The major clinical manifestation of multiple myeloma is related to the osteolytic bone destruction. The bone disease can lead to pathologic fractures, spinal cord compression, hypercalcemia, and pain. It is also a major cause of morbidity and mortality in these patients. These patients frequently require radiation therapy, surgery and analgesic medications. Bisphosphonates are specific inhibitors of osteoclastic activity, and these agents have been evaluated in myeloma patients with bone disease during the past 15 years. Several large randomized trials have been conducted in myeloma patients also receiving chemotherapy. Orally administered bisphosphonates have shown little ability to slow the development of skeletal complications in these patients. In contrast, more potent intravenous monthly infusions of either pamidronate or zoledronic acid have reduced the skeletal complications among these patients and are now a mainstay of myeloma therapy. A number of other types of new anti-bone-resorptive agents are also in early clinical development.
引用
收藏
页码:653 / 672
页数:20
相关论文
共 112 条
[1]   Serum markers of bone metabolism in multiple myeloma: Prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP) [J].
Abildgaard, N ;
Bentzen, SM ;
Nielsen, JL ;
Heickendorff, L .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 96 (01) :103-110
[2]   Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy [J].
Abildgaard, N ;
Brixen, K ;
Kristensen, JE ;
Eriksen, EF ;
Nielsen, JL ;
Heickendorff, L .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (02) :235-242
[3]  
Abildgaard N, 1996, EUR J HAEMATOL, V57, P370
[4]  
*ACT LEUK GROUP B, 1972, NEW ENGL J MED, V286, P1283
[5]   PALLIATIVE RADIOTHERAPY IN PLASMA-CELL MYELOMA [J].
ADAMIETZ, IA ;
SCHOBER, C ;
SCHULTE, RWM ;
PEEST, D ;
RENNER, K .
RADIOTHERAPY AND ONCOLOGY, 1991, 20 (02) :111-116
[6]  
Agren B, 1997, ACTA RADIOL, V38, P144
[7]  
Ågren B, 1998, ACTA RADIOL, V39, P36
[8]   Urinary N-telopeptide levels in multiple myeloma patients, correlation with Tc-99m-sestaMIBIscintigraphy and other biochemical markers of disease activity [J].
Alexandrakis, MG ;
Kyriakou, DS ;
Passam, FH ;
Malliaraki, N ;
Vlachonikolis, IG ;
Karkavitsas, N .
HEMATOLOGICAL ONCOLOGY, 2003, 21 (01) :17-24
[9]  
Angtuaco EJ, 1999, RADIOLOGY, V213P, P294
[10]  
Angtuaco EJ, 2001, RADIOLOGY, V221, P138